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966Chronic kidney disease and the short-term risk of
mortality and amputation in patients hospitalized
for peripheral artery disease
Philippe Lacroix, MD,a,c Victor Aboyans, MD, PhD,b,c Ileana Desormais, MD,a,c Thierry Kowalsky, MD,a
Jean Pierre Cambou, MD,d,e Joel Constans, MD, PhD,f and Alessandra Bura Rivière, MD, PhD,d,e on behalf
of the COPART investigators, Limoges, Toulouse, and Bordeaux, France
Objective: The aim of the present study was to determine the prevalence of chronic kidney disease (CKD) and its prog-
nostic value in patients hospitalized for lower extremity peripheral artery disease (PAD).
Methods: Data from the COhorte des Patients ARTériopathes registry, a prospective multicenter, observational study of
consecutive patients hospitalized for PAD in academic hospitals of southwestern France, were analyzed. All the subjects
were in Rutherford grade $ 3, and 55.6% were in grade $5-6. Associations between CKD and 1-year mortality, as well as
amputation rates, were evaluated by Cox analysis. Kaplan-Meier survival curves were analyzed according to estimated
glomerular ﬁltration rate (eGFR).
Results: From May 2004 to January 2009, we enrolled 1010 patients. They were classiﬁed into four groups according to
the eGFR: 21.7% were in group 1 ($90 mL/min per 1.73 m2), 34% in group 2 (60-89 mL/min per 1.73 m2), 32.2% in
group 3 (30-59 mL/min per 1.73 m2), and 12.1% in group 4 (<30 mL/min per 1.73 m2 including dialysis). All-cause
mortality was 25.1% at 1 year. The rate of major amputation was 26.3%. Mortality rates were, respectively, at 16%,
18%, 31.7%, and 44.3% (P < .0001) in groups 1 to 4. The major amputation rates were at 23.7%, 21.5%, 28%, and 40.2%
(P [ .0006), respectively. The presence of severe CKD (group 4) was associated with all-cause mortality (hazard ratio,
1.84; 95% conﬁdence interval, 1.02-3.32; P [ .044). In contrast, the risk of amputation was not associated with CKD
after adjustments to risk factors.
Conclusions: The prevalence of CKD in patients hospitalized for PAD is high. CKD is an independent predictor of 1-year
mortality, but is not an independent predictor of limb amputation. (J Vasc Surg 2013;58:966-71.)2Lower extremity peripheral artery disease (PAD) is
highly prevalent in the community, close to 13% after the
age of 65.1 It is associated with increased cardiovascular
and all-cause mortality.2 More recently, chronic kidney
disease (CKD) is also identiﬁed as a strong risk marker of
cardiovascular events and death.3,4 In a large population
study, Go et al3 demonstrated that the risk of cardiovas-
cular events rises sharply in subjects with an estimated
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CKD should be considered as a relevant risk factor for
mortality, regardless of the hypertensive or diabetic
status.5,6 Previous studies have described an association
between CKD and PAD.7 PAD is prevalent in patients
with CKD,8 particularly among those at the end-stage
disease requiring dialysis.9,10 Conversely, CKD appears
common in the presence of PAD.11 In a vascular laboratory
population, patients both with CKD and PAD had a signif-
icantly higher long-term mortality risk than patients with
either disease alone.7 In selected groups of patients with
PAD, CKD was predictive of mortality or amputation after
revascularization.12,13 In a national patient care database in
the U.S., including advanced cases of PAD,14 both
moderate and severe CKD were associated with increased
odds of death. In that study, a positive association was
described between PAD and CKD severity. However,
that study was limited to male patients. Similar ﬁndings
on the association between decreased renal function and
poorer prognosis were reported in patients undergoing
endovascular procedures.15 These studies are mostly
focused on a subgroup of patients, and data regarding large
series of consecutive hospitalized patients are sparse. Also,
the prognostic value of CKD has been barely studied
concomitantly regarding the general (mortality and cardio-
vascular events) and local (limb outcome) prognosis. Data
from the COhorte des Patients ARTériopathes (COPART)
registry, a prospective multicenter study collecting exhaus-
tive data on consecutive patients hospitalized for PAD
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a unique opportunity to assess the current prevalence and
prognostic aspects of CKD in case of severe PAD.
METHODS
The COPART registry is an ongoing multicenter
prospective observational cohort study including consecu-
tive patients hospitalized speciﬁcally for a clinical episode
of PAD in the three academic centers of Bordeaux,
Limoges, and Toulouse, France since May 2004. Details
regarding this registry have already been published else-
where.16 Initial clinical history, disease characteristics, and
therapeutic data were collected. The enrolled patients
gave their informed consent to participate. The study was
approved by the Ethic Committee of Toulouse University
Hospital. Initial clinical, biological, and imaging data, as
well as in-hospital events and therapeutic strategies, were
collected. The Modiﬁcation of Diet in Renal Disease
(MDRD) formula17 was used for the estimation of glomer-
ular ﬁltration rate (eGFR) at admission. CKD was stratiﬁed
according the Kidney Disease Outcome Quality Initiative18
into four groups: group 1, eGFR $90 mL/min per
1.73 m2; group 2, 60-89 mL/min per 1.73 m2; group 3,
30-59 mL/min per 1.73 m2; and group 4, <30 mL/min
per 1.73 m2. After the initial hospitalization, all the patients
were followed for 12 months. For this purpose, mortality
data at registrar’s ofﬁces were consulted, and nonfatal
events were retrieved through the hospitals’ ﬁles, mailing,
or phone contacts to the physicians or the patients if neces-
sary. The primary outcome was total mortality. The
secondary outcome was the occurrence of amputation
during the 1-year follow-up. The current report is
based on a database locked on January 31, 2010 for the
follow-up.
Statistical analysis. Continuous variables are exp-
ressed as mean 6 standard deviation. Categorical variables
are expressed as frequencies and percentages. Comparisons
were made with c2 test (or Fisher exact tests, when appro-
priate) for discrete variables and by Kruskal-Wallis test for
continuous variables. Cumulative incidence curves were
constructed for selected outcomes using the Kaplan-Meier
method. Cox proportional hazards model was carried out
to study the association between eGFR levels and outcome.
Three models were analyzed; the ﬁrst model included age,
gender, Rutherford stage, and center. In the second model,
the cardiovascular risk factors were added. Covariates
included in the third model were extended to cardiovas-
cular history (stroke, transient ischemic attack, heart failure,
acute coronary syndrome), heart rate, C-reactive protein,
hemoglobin level, and treatments at discharge (antiplatelet
drugs, beta-blockers, statins, and renin-angiotensin system
inhibitors). A P value <.05 was set for statistical signiﬁ-
cance. Statistical analyses were performed using Statview
4.0 (SAS institute, Cary, NC).
RESULTS
From May 17, 2004 to January 31, 2009, 1079
consecutive patients were hospitalized for PAD in one ofthe three medical centers and included in the registry. At
baseline, the mean eGFR was 68 mL/min/1.73 m2. Eigh-
teen patients (1.7%) were lost during follow-up, and 51
others were excluded because of missing data (eg, serum
creatinine), leading to 1010 patients analyzed in this
report. The overall study population as well as the four
eGFR groups are presented in Table I.
There was an association between decreasing levels of
eGFR and increasing rates of history of coronary artery
disease, heart failure, smoking, diabetes, hypertension,
and Rutherford grades, as well as age and C-reactive
protein levels. Hemoglobin was found decreased along
with eGFR groups. Subjects in the lowest eGFR group
were more likely to be female and less likely to be treated
with renin-angiotensin system inhibitors or take beneﬁt
from revascularization (Table I).
At 1 year, 25.1% of the patients were deceased. The
major amputation rates were, respectively, 1.7%, 2.4%,
and 26.3% (Table II). The risk of death and amputation
increased with the severity of the renal impairment. The
Fig shows Kaplan-Meier curves for total mortality and
amputation, according to the eGFR levels. One-year
mortality was respectively at 16%, 18%, 31.7%, and 44.3%
in groups 1 through 4 (P < .0001). Similarly, major ampu-
tation rates were at 23.7%, 21.5%, 28%, and 40.2%
(P ¼ .0006), respectively.
In the multivariate analysis, although a trend to an
increased risk of death was found across the four eGFR
groups (Table III), a signiﬁcant association was only found
regarding an increased risk of mortality (84%) in the severe
CKD group (group 4). Conversely, no signiﬁcant associa-
tion was found between different categories of renal failure
and amputation (P > .79; Table III).
DISCUSSION
In this multicenter cohort of subjects hospitalized for
PAD, we demonstrated that impaired renal function esti-
mated at admission is frequent and predictive of death or
cardiovascular events 1 year after discharge. Signiﬁcant
association was limited to severe CKD in the multivariate
analysis. In contrast, no association between CKD and
amputation was found after adjustments to confounders.
In a large survey including 5787 male veterans
admitted for limb pain at rest, ischemic ulceration, or
gangrene, O’Hare et al14 reported a signiﬁcant association
between CKD and mortality, with increased odds of 1-year
death respectively at 1.32 and 2.97 in patients with an
eGFR of 30 to 59 mL/min per 1.73 m2 and <30 mL/min
per 1.73 m2. In a tertiary care center cohort of 208 patients
undergoing endovascular revascularization for CLI,15
eGFR was also an independent predictor of 1-year
mortality, with death rates respectively at 26.5%, 30.1%,
and 31.9% in patients with normal renal function,
moderate renal dysfunction, and severe CKD. The relation-
ship between CKD and the risk of death after vascular
surgery was also illustrated in a meta-analysis of 25 studies
including 996 patients overall with end-stage CKD who
underwent infrainguinal revascularization19; the 1-year
Table II. One-year events by levels of renal function
Groups
Total
(n ¼ 1010 )
Group 1
(n ¼ 219)
Group 2
(n ¼ 344)
Group 3
(n ¼ 325)
Group 4
(n ¼ 122) P
Overall mortality 254 (25.1) 35 (16.0) 62 (18.0) 103 (31 .7) 54 (44.3) <.0001
Amputations 283 (28.0) 53 (24.2) 80 (23.3) 98 (30.1) 52 (42.6) .0003
Major amputations 266 (26.3) 52 (23.7) 74 (21.5) 91 (28.0) 49 (40.2) .0006
eGFR, Estimated glomerular ﬁltration rate.
Data are presented as number (%).
Four groups: group 1, normal ($90 mL/min per 1.73 m2); group 2, mild eGFR (60-89 mL/min per 1.73 m2); group 3, moderate eGFR (30-59 mL/min
per 1.73 m2); group 4. severe eGFR (<30 mL/min per 1.73 m2).
Table I. Baseline characteristics of the population by level of renal function
Groups
Total
(n ¼ 1010)
Group 1
(n ¼ 219)
Group 2
(n ¼ 344)
Group 3
(n ¼ 325)
Group 4
(n ¼ 122) P
Age, years 70.7 6 2.8 64.0 6 13.1 68.9 6 12.0 76.4 6 11.0 72.9 6 11.8 <.0001
Men 720 (71.3) 186 (84.9) 260 (75.6) 203 (58.2) 71 (58.2) <.0001
Clinical history
PAD revascularizationa 305 (30.2) 82 (37.4) 102 (29.7) 89 (27.4) 32 (26.2) .054
Amputation 163 (16.1) 34 (15.5) 37 (10.8) 60 (18.5) 32 (26.2) .0005
Coronary artery disease 380 (37.1) 49 (22.4) 123 (35.8) 141 (43.4) 67 (54.7) <.0001
Heart failure 128 (12.8) 12 (5.6) 20 (5.8) 69 (21.5) 27 (22.3) <.0001
Cerebrovascular disease 155 (15.3) 26 (11.9) 56 (16.3) 50 (15.4) 23 (18.9) .331
CAD and/or CVD 463 (45.8) 68 (31.1) 150 (43.6) 167 (51.4) 78 (63.9) <.0001
Risk factors and biological data
Hyperlipidemia 521 (52.6) 116 (53.0) 194 (56.4) 165 (50.8) 56 (45.9) .201
Diabetes mellitus 445 (44.1) 71 (32.4) 126 (36.6) 167 (51.4) 81 (66.4) <.0001
Hypertension 777 (76.9) 132 (60.3) 257 (74.7) 282 (86.8) 106 (86.9) <.0001
Smoking 242 (24.5) 99 (46.3) 91 (26.5) 40 (12.7) 12 (10.3) <.0001
Heart rate, bpm 76.4 (14.5) 78.4 (13.7) 76.4 (14.1) 74.8 (14.4) 77.8 (17.9) <.0001
C-reactive protein, mg/dL 54.5 (71.8) 53.3 (67.8) 47.3 (72.1) 50.3 (61.2) 88.8 (67.8) <.0001
Hemoglobin, g/dL 12.5 (2.0) 12.9 (2.1) 13.0 (2.0) 12.1 (1.9) 11.5 (1.7) <.0001
Clinical presentation (Rutherford grades)
Grade 3 254 (25.1) 74 (33.8) 119 (34.6) 56 (17.2) 5 (4.1) <.0001
Grade 4 88 (8.7) 28 (12.8) 34 (9.9) 22 (6.8) 4 (3.3) <.0001
Grade 5-6 562 (55.6) 93 (42.5) 154 (44.8) 212 (65.2) 103 (84.4) <.0001
Acute limb ischemia 106 (10.5) 24 (11.0) 37 (10.8) 35 (10.8) 11 (8.2) <.0001
Interventions
Endovascular therapy 291 (28.8) 43 (19.6) 108 (31.4) 99 (30.5) 41 (33.6) .077
Bypass surgery 120 (11.9) 39 (17.8) 47 (13.7) 25 (7.7) 9 (7.4) .001
Amputation 124 (12.3) 32 (14.6) 29 (8.4) 38 (11.7) 25 (20.5) .004
Major amputation 107 (10.6) 31 (14.2) 23 (6.7) 31 (9.5) 22 (18) .001
Treatment at discharge
Statins 653 (64.7) 139 (65.5) 236 (68.6) 210 (64.8) 68 (55.7) .081
Renin-angiotensin system inhibitors 545 (54.0) 107 (48 .9) 206 (59.9) 191 (59.0) 41 (33.6) <.0001
Beta-blockers 266 (26.4) 42 (19.2) 91 (26.5) 98 (30.2) 35 (28.7) .034
Antiplatelet drugsb 751 (74.4) 169 (77.2) 266 (77.3) 234 (72.2) 82 (67.2) .088
CAD, Coronary artery disease; CVD, cerebrovascular disease; eGFR, estimated glomerular ﬁltration rate; PAD, peripheral artery disease.
Data are presented as mean 6 standard deviation or number (%).
Four groups: group 1, normal ($90 mL/min per 1.73 m2); group 2, mild eGFR (60-89 mL/min per 1.73 m2); group 3, moderate eGFR (30-59 mL/min
per 1.73 m2); group 4. severe eGFR (<30 mL/min per 1.73 m2).
aEndovascular or surgical revascularization.
bFour hundred one (39.7%) additional patients were treated with vitamin K antagonists.
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studies included mostly patients with critical limb ischemia;
25.1% of our patients were in Rutherford grade 3, so our
data suggest that the association between CKD and
mortality is not limited to the most severe cases of PAD
but the full spectrum of clinical presentations leading tohospitalization for PAD. Another strength of our study is
that the association between severe CKD and mortality is
robust to a large multivariate analysis including several con-
founding factors as well as the clinical severity of PAD. In
another study,20 CKD evaluated with the MDRD formula
was a better predictor of risk of death or acute myocardial
A≥
B
≥
Fig. Survival curves in patients with peripheral artery disease (PAD) according to estimated glomerular ﬁltration rate
(eGFR) groups. A, Mortality. B, Amputations (overall).
Table III. Association of eGFR groups and outcomes
Outcomes
Hazard ratio (95% conﬁdence interval), P value
Unadjusted Model 1 Model 2 Model 3
Mortality
$90 mL/min/1.73 m2 1 (reference) 1 (reference) 1 (reference) 1 (reference)
60-89 mL/min/1.73 m2 1.17 (0.77-1.77), NS 1.07 (0.70-1.63), NS 1.13 (0.72-1.77), NS 1.04 (0.61-1.75), NS
30-59 mL/min/1.73 m2 2.23 (1.52-3.28),
<.0001
1.56 (1.03-2.37),
.037
1.65 (1.05-2.58),
.030
1.26 (0.73-2.16), NS
<30 mL/min/1.73 m2 3.44 (2.25-5.27),
<.0001
2.53 (1.62-3.97),
<.0001
2.55 (1.57-4.14), .0002 1.84 (1.02-3.32),
.044
Amputation
$90 mL/min/1.73 m2 1 (reference) 1 (reference) 1 (reference) 1 (reference)
60-89 mL/min/1.73 m2 0.95 (0.67-1.34), NS 0.95 (0.66-1.37), NS 0.91 (0.62-1.34), NS 0.84 (0.55-1.29), NS
30-59 mL/min/1.73 m2 1.37 (0.98-1.92), NS 1.06 (0.73-1.55), NS 0.98 (0.66-1.47), NS 0.99 (0.63-1.57), NS
<30 mL/min/1.73 m2 2.37 (1.62-3.48),
<.0001
1.47 (0.97-2.21), NS 1.34 (0.86-2.07), NS 1.07 (0.64-1.80), NS
eGFR, Estimated glomerular ﬁltration rate; Model 1, adjusted for age, gender, Rutherford stage, and center; Model 2, model 1 þ cardiovascular risk factors
(smoking, hypertension, diabetes, dyslipidemia); Model 3, model 2 þ heart rate þ C-reactive protein þ hemoglobin þ history of coronary artery disease þ
history of cerebrovascular disease þ history of heart failure þ treatments at discharge (statins, renin-angiotensin system inhibitors, beta-blockers, antiplatelet
drugs); NS, not signiﬁcant.
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risk factors. All these results support the relevance of CKD
to predict death in PAD patients.
In contrast to previous reports, our study does not
support the hypothesis of an independent association
between CKD severity and risk of amputation. After a large
adjustment particularly for Rutherford stage, CKD does
not inﬂuence the local prognosis. The aforementioned
study by O’Hare et al14 reported increasing rates of
gangrene and ulcers with declining renal function, but
less confounders were included in the analysis. In a cohort
of 9932 patients undergoing surgical revascularization,13those under dialysis were reported at increased risk of
amputation (odds ratio, 2.46; 95% conﬁdence interval,
1.74-3.47); but in this study, the analysis was not adjusted
for PAD severity. The poorer outcome in patients with
dialysis may reﬂect only more severe and progressed PAD
prior to surgery. In a retrospective study21 including
patients with critical limb ischemia undergoing infraingui-
nal bypasses, CKD was associated with a decreased rate
of limb salvage, with a similar bypass patency rate. In
another retrospective study, Fernandez et al22 reported
a 46% amputation rate after tibial angioplasty in case of
end-stage renal disease vs 18% among nondialyzed patients.
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964 patients under dialysis was 21.4%.19 In the univariate
analysis, we described rates of amputation at 21.5% in
case of mild CKD vs 40.2% in case of severe CKD, but
this association was no longer signiﬁcant in the multivariate
analysis. The recently published prospective data from Wil-
lenberg et al15 were in line with our ﬁndings, since they
found no signiﬁcant association between renal function
and limb salvage. Moreover, in an aforementioned
survey,20 the MDRD values did not predict the need for
vascular reintervention. These last data and our results
suggest that the risk of amputation is not independently
increased by the presence of CKD.
Regarding the prevalence of CKD among patients
hospitalized for PAD, our results were close to those previ-
ously reported; in a cohort of 5787 male patients admitted
for critical limb ischemia,14 30% had an eGFR of 30 to
59 mL/min per 1.73 m2, and 8% had <30 mL/min per
1.73 m2. In our population, almost 45% of the patients
had eGFR of <60 mL/min per 1.73 m2. In such a popula-
tion, CKD was not only predictive of mortality but also
highly prevalent.
The present study has some limitations. The necessity
to exclude 69 patients because of lacking data is regret-
table, but it should not cause major selection bias since
these patients were comparable to the included patients
regarding baseline data. In 18 cases, the patients were
lost during the follow-up despite the inquiries. Unfortu-
nately, 51 cannot be included because of missing values
that were mandatory in order to be classiﬁed or analyzed.
Hemodynamic evaluations, including ankle-brachial index
or toe-brachial index, were not available in many cases,
but the Rutherford classiﬁcation provided insights on the
ischemia severity. The majority of the patients were in
Rutherford 5 to 6 grade corresponding with severe PAD.
The mode of revascularization and the localization of
PAD lesions were not included in the analysis. However,
we do not think this is a major concern because our results
on mortality are consistent with those previously reported.
A revascularization was conducted in only 40% of the cases.
Two of the participating centers were vascular medicine
departments, where Rutherford class 5-6 patients were
mainly managed in the absence of any possibility for revas-
cularization. Although a registry presents limitations,
we are conﬁdent regarding the follow-up of death and
amputation; the death criteria is easily retrieved, and the
amputations were done in the participating hospitals. Re-
garding the amputation rates, in routine indications, they
were selected according to the TASC classiﬁcation.23
Finally, our statistical model was adjusted with all the usual
signiﬁcant confounders, but we cannot exclude the contri-
bution of other unmeasured confounders. We did not
assess the evolution of the renal function during the
follow-up.
In conclusion, CKD is a frequent condition in patients
hospitalized for PAD, and severe CKD is associated with
higher mortality, but the limb outcome seems not indepen-
dently impacted by this condition. Appropriate optimaltreatments24 should be considered in order to lower
mortality risk. Considering the results on the limb risk,
these patients should not be excluded from revasculariza-
tion protocols.AUTHOR CONTRIBUTIONS
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